[{"Assets_0_Q2_USD":642681000.0,"CommonStockSharesOutstanding_0_Q2_shares":40954969.0,"NetIncomeLoss_1_Q2_USD":2564000.0,"NetIncomeLoss_2_Q2_USD":-8116000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q2_USD":80717000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_2_Q2_USD":155004000.0,"StockholdersEquity_0_Q2_USD":290513000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q2_shares":41694000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_2_Q2_shares":40751000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q2_shares":40796000.0,"WeightedAverageNumberOfSharesOutstandingBasic_2_Q2_shares":40751000.0,"Ticker":"PCRX","CIK":"1396814","name":"PACIRA PHARMACEUTICALS, INC.","OfficialName":"Pacira BioSciences Inc. Common Stock","form":"10-Q","period":"20180630","fy":"2018.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"3316489486.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20180802"}]